• The hemostatic efficacy of desmopressin, an analog of vasopressin, was first discovered in Italy in 1977 by Mannucci and colleagues. (wikipedia.org)
  • Background/Aim: Desmopressin is a synthetic analogue of the antidiuretic hormone vasopressin. (iiarjournals.org)
  • Desmopressin (1-deamino-8-D-arginine vasopressin, also known as DDAVP) is a synthetic analog of the antidiuretic hormone vasopressin, that targets multiple physiological pathways including an oncogenic pathway ( 5 ). (iiarjournals.org)
  • As arginine-vasopressin (AVP) plays an important role in the activation of HPA axis during stress, the present study investigated ACTH and cortisol secretory response induced by an AVPrelated peptide desmopressin (ddAVP) in patients with major depression. (uandes.cl)
  • DDAVP (which stands for 1-deamino-8-D-arginine vasopressin) Nasal Spray is made up of antidiuretic hormone called desmopressin. (mydrugcenter.com)
  • DDAVP Nasal Spray (Desmopressin) is a man made form of vasopressin (a natural hormone found in the pituitary gland) which has an effect on various body functions such as affecting blood pressure, kidney function, and regulating how the body uses water. (mydrugcenter.com)
  • DDAVP Nasal Spray is prescribed to patients with those conditions to replace the loss vasopressin with desmopressin to control their possible excessive thirst and urination due to the condition. (mydrugcenter.com)
  • Investigation of mechanism of desmopressin binding in vasopressin V2 receptor versus vasopressin V1a and oxytocin receptors: molecular dynamics simulation of the agonist-bound state in the membrane-aqueous system. (drugbank.com)
  • Desmopressin ([1-deamino, 8-D]AVP, dDAVP) is strong selective V2R agonist with negligible pressor and uterotonic activity. (drugbank.com)
  • Type 1 VWD can often be effectively managed by treatment with DDAVP (1-deamino-8- D -arginine vasopressin, desmopressin), which produces a two- to threefold increase in plasma VWF level due to release from endothelial storage sites in the vessel wall. (mhmedical.com)
  • 1-desamino-8-D-arginine vasopressin (DDAVP) is considered a standard vasopressin V2 receptor-selective agonist with a potent antidiuretic effect through V2 receptor without the induction of vasoconstriction through V1a receptor. (nih.gov)
  • However, the agonistic activity of DDAVP against the other vasopressin receptor, V1b (or V3), which can accumulate intracellular Ca2+ and which we recently cloned, has not been clarified. (nih.gov)
  • Hence, we compared the characteristics of DDAVP on V1b receptor with those on the other vasopressin receptors. (nih.gov)
  • In binding experiments, DDAVP more strongly inhibited [3H]arginine vasopressin binding to V1b than to V2 receptor (Ki: 5.84 nM vs 65.9 nM). (nih.gov)
  • However, DDAVP behaved as a partial agonist toward rat V1b receptor (intrinsic activity: 0.7, EC50: 43.5 nM), while there was no significant difference in the agonistic properties of arginine vasopressin on human and rat V1b receptor. (nih.gov)
  • These findings will allow us to better understand the physiological role of V1b receptor in pancreatic beta cells and in the renal inner medullary collecting duct, and help us to identify as yet unknown vasopressin receptors through which DDAVP cause the accumulation of intracellular Ca2+ in other tissues. (nih.gov)
  • therefore, the majority of patients with VWD achieve a clinical and laboratory remission of the disease during pregnancy, and treatment with 1-deamino-8-D-arginine vasopressin (DDAVP) or blood transfusion is usually not necessary. (renalandurologynews.com)
  • 2. Platelet retention in glass bead columns, platelet aggregation in vitro , β-thromboglobulin and 6-oxo-prostaglandin F 1α were monitored in six normal male volunteers before and after an acute rise of von Willebrand factor, as induced by the intravenous administration of 1-deamino-8-d-arginine vasopressin (DDAVP). (portlandpress.com)
  • The ddAVP challenge promoted a robust secretion of ACTH only in late responders, suggesting a different sensitivity of pituitary vasopressin receptor. (uandes.cl)
  • Anticholinergics or 1-deamino-[8-D-arginine]-vasopressin (dDAVP) were intravenously administered. (bvsalud.org)
  • In this paper, the interactions responsible for binding of dDAVP to vasopressin V2 receptor versus vasopressin V1a and oxytocin receptors has been examined. (drugbank.com)
  • Hyponatremia was induced by subcutaneous infusion of 1‐deamino‐[8‐D‐arginine]‐vasopressin (dDAVP) (5ng/h) to rats fed a nutritionally balanced liquid diet, and plasma [Na+] was maintained ≤115 mmol/l for 10-12 days. (elsevierpure.com)
  • The two evolutionarily related peptides oxytocin (OXT) and arginine vasopressin (AVP) are known to be associated with a variety of physiological and psychological processes via the association of OXT with three types of AVP receptors. (bvsalud.org)
  • The vasopressin V2 receptor (V2R) belongs to the Class A G protein-coupled receptors (GPCRs). (drugbank.com)
  • AVP resistance (AVP-R) (nephrogenic diabetes insipidus) arises from defective or absent receptor sites at the cortical collecting duct segment of the nephron (X-linked, vasopressin V2 receptor deficiency, locus Xq28) or defective or absent aquaporin, the protein that transports water at the collecting duct (autosomal recessive, locus 12q13). (medscape.com)
  • Oxytocin and/or vasopressin seem to be regulators of gastric emptying during physiological conditions, since the receptor antagonist atosiban delayed the GER. (biomedcentral.com)
  • AVP disorders are due either to (1) deficient secretion of antidiuretic hormone (ADH) by the pituitary gland (AVP-D) or to (2) renal tubular unresponsiveness to vasopressin (AVP-R). (medscape.com)
  • In conditions like diabetes insipidus ("water diabetes") and in certain cases of head injury or brain surgery, the body does not produce enough vasopressin. (mydrugcenter.com)
  • Chronic hyponatremia is known to cause inhibition of pituitary vasopressin (AVP) and oxytocin (OT) secretion in response to most physiological stimuli, as well as a marked inhibition of synthesis of these peptides. (elsevierpure.com)
  • V2R is expressed in the renal collecting duct (CD), where it mediates the antidiuretic action of the neurohypophyseal hormone arginine vasopressin (CYFQNCPRG-NH2, AVP). (drugbank.com)
  • AVP-D with an autosomal dominant pattern inheritance is due to a mutation in the prepro-arginine vasopressin ( prepro-AVP2 ) gene, mapped to locus 20p13. (medscape.com)
  • A synthetic analog of the pituitary hormone, ARGININE VASOPRESSIN . (nih.gov)
  • A study of 78 patients who underwent elective transsphenoidal adenomectomy to remove a pituitary tumor or other lesions within the pituitary fossa at a single center in the UK suggests that postoperative plasma levels of copeptin - a surrogate marker for levels of arginine vasopressin (antidiuretic hormone) - can rule out development of central (neurogenic) diabetes insipidus caused by a deficiency of arginine vasopressin following pituitary surgery . (medscape.com)
  • Central DI (CDI), better now referred to as arginine vasopressin (AVP)-deficiency, is the most common form of DI resulting from deficiency of the hormone AVP from the pituitary. (bvsalud.org)
  • An our previous study found that UT-B knockout caused urea accumulation in the bladder urothelial cells, which created an imbalance between the arginine-ornithine-polyamine pathway and the arginine-citrulline-nitric oxide pathway. (biomedcentral.com)